ATE274923T1 - Stimulierung des immunsystems - Google Patents

Stimulierung des immunsystems

Info

Publication number
ATE274923T1
ATE274923T1 AT99936455T AT99936455T ATE274923T1 AT E274923 T1 ATE274923 T1 AT E274923T1 AT 99936455 T AT99936455 T AT 99936455T AT 99936455 T AT99936455 T AT 99936455T AT E274923 T1 ATE274923 T1 AT E274923T1
Authority
AT
Austria
Prior art keywords
receptors
stimulating
immune system
inhibitor
immune response
Prior art date
Application number
AT99936455T
Other languages
English (en)
Inventor
Karl-Hermann Schlingensiepen
Reimar Schlingensiepen
Wolfgang Brysch
Original Assignee
Biognostik Ges
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biognostik Ges filed Critical Biognostik Ges
Application granted granted Critical
Publication of ATE274923T1 publication Critical patent/ATE274923T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Electrotherapy Devices (AREA)
AT99936455T 1998-06-10 1999-06-10 Stimulierung des immunsystems ATE274923T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98110709 1998-06-10
EP98113974 1998-07-25
PCT/EP1999/004013 WO1999063975A2 (en) 1998-06-10 1999-06-10 A method for stimulating the immune system

Publications (1)

Publication Number Publication Date
ATE274923T1 true ATE274923T1 (de) 2004-09-15

Family

ID=26149338

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99936455T ATE274923T1 (de) 1998-06-10 1999-06-10 Stimulierung des immunsystems

Country Status (9)

Country Link
US (1) US8629117B2 (de)
EP (1) EP1089764B1 (de)
JP (1) JP4627369B2 (de)
AT (1) ATE274923T1 (de)
AU (1) AU5154999A (de)
CA (1) CA2334960C (de)
DE (1) DE69919869T2 (de)
ES (1) ES2226414T3 (de)
WO (1) WO1999063975A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884787B2 (en) 2001-07-14 2005-04-26 Isis Pharmaceuticals, Inc. Antisense modulation of transforming growth factor-beta 3 expression
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2381006A1 (en) * 1999-09-17 2001-03-22 Nicholas M. Dean Antisense modulation of transforming growth factor-.beta. expression
EP1133994A1 (de) 2000-03-11 2001-09-19 Biognostik Gesellschaft für biomolekulare Diagnostik mbH Verfahren zür Umwandlung des immunosuppresive effekts von MIA (Melanoma Inhibitory Activity)
EP1191097A1 (de) * 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induktion von "exon-skipping" in eukaryotischen Zellen
DK1446162T3 (da) 2001-08-17 2008-12-08 Coley Pharm Gmbh Kombinationsmotiv-immunstimulatoriske oligonukleotider med forbedret aktivitet
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
PT2284266E (pt) * 2002-11-14 2013-12-17 Thermo Fisher Scient Biosciences Inc Siarn contra tp53
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
EP1444989A1 (de) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensibilisierung von Zellen für die Apoptose durch selektive Blockade von Zytokinen
EP1694840A2 (de) * 2003-12-19 2006-08-30 Antisense Pharma GmbH Kombinations-therapie die ein tgf-beta antagonisten mit einem chemotherapeutikum assoziiert
EP2248895B8 (de) 2003-12-19 2016-09-21 Autotelic LLC Kombinations-therapie die ein TGF-beta Antagonisten mit einem Chemotherapeutikum assoziiert
JP5650367B2 (ja) * 2004-02-27 2015-01-07 アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物
EP1568383A3 (de) * 2004-02-27 2005-11-16 Antisense Pharma GmbH Verwendung eines Oligonukleotide oder seiner aktiven Ableitung für die Zubereitung einer pharmazeutische Zusammensetzung zur Hemmung der Metastasenbildung in Krebsbehandlung
WO2005110464A2 (en) * 2004-05-14 2005-11-24 Oregon Health & Science University Irx5 inhibition as treatment for hyperproliferative disorders
CN101277704A (zh) 2005-04-12 2008-10-01 因特拉迪格姆公司 用于治疗癌症及其它新血管生成疾病的RNAi治疗剂的组合物和方法
US7893244B2 (en) 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
CA2591586A1 (en) 2005-05-05 2006-11-09 Antisense Pharma Gmbh Dosage of oligonucleotides
EP1974740A4 (de) * 2005-10-24 2010-09-01 Proyecto Biomedicina Cima Sl Verwendung von tgf-beta 1 inhibitor-peptiden bei der herstellung eines mittels zur modulierung der immunantwort
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
ES2639852T3 (es) 2007-10-26 2017-10-30 Academisch Ziekenhuis Leiden Medios y métodos para contrarrestar los trastornos musculares
EP2119783A1 (de) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel
US8822425B2 (en) 2008-11-14 2014-09-02 Antisense Pharma Gmbh Dosage of oligonucleotides suitable for the treatment of tumors
KR101410560B1 (ko) * 2008-11-14 2014-07-01 안티센스 파마 게엠베하 종양의 치료에 적합한 올리고뉴클레오티드의 용량
US20120252869A1 (en) * 2009-07-24 2012-10-04 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
AU2011263642B2 (en) 2010-06-11 2014-09-04 Isarna Therapeutics Gmbh Method for selective oligonucleotide modification
EP2598639A4 (de) 2010-07-28 2014-08-13 Alcon Res Ltd Auf sirna zielende vegfa und in-vivo-behandlungsverfahren damit
EP2453017A1 (de) * 2010-11-12 2012-05-16 Antisense Pharma GmbH Oligonucleotide zur Verwendung bei der Prophilaxe und/oder Behandlung von TGF-beta1- und TGF-beta2-, TGF-beta2- und TGF-beta3-, TGF-beta1- und TGF-beta3- oder TGF-beta1-, TGF-beta2- und TGF-beta3-mRNA-Überexpressionskrankheiten
CN112251436A (zh) 2012-01-27 2021-01-22 比奥马林技术公司 治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
WO2017138924A1 (en) 2016-02-09 2017-08-17 Autotelic Llc Compositions and methods for treating pancreatic cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2738392A (en) 1991-11-11 1993-05-13 Ciba-Geigy Ag Novel hybrid transforming growth factors
US5523389A (en) 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
DE69429617T2 (de) * 1993-04-30 2002-08-22 Biognostik Ges Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)
WO1994029452A2 (en) 1993-06-09 1994-12-22 Ribozyme Pharmaceuticals, Inc. Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease
WO1995000103A2 (en) * 1993-06-15 1995-01-05 Il-Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
US5731294A (en) 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
US5772995A (en) * 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
EP0910634A2 (de) 1996-04-17 1999-04-28 Hoechst Marion Roussel Deutschland GmbH Antisens-inhibitoren der expression des vaskulären epithel-wachstumsfaktors (vegf/vpf)
JPH1052285A (ja) 1996-05-23 1998-02-24 Toagosei Co Ltd アンチセンス核酸の調製方法
DE69725878T2 (de) * 1996-08-13 2004-07-29 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Zusammensetzungen zur polynukleotidabgabe
AU6287198A (en) 1997-03-07 1998-09-29 Hospital For Sick Children Methods to diagnose a required regulation of trophoblast invasion
EP0945507A1 (de) 1998-03-27 1999-09-29 Boehringer Mannheim Gmbh Tumorspezifische Expressionskontrollregion und deren Verwendung

Also Published As

Publication number Publication date
JP2002517434A (ja) 2002-06-18
WO1999063975A2 (en) 1999-12-16
DE69919869D1 (de) 2004-10-07
CA2334960A1 (en) 1999-12-16
JP4627369B2 (ja) 2011-02-09
CA2334960C (en) 2012-01-03
EP1089764A2 (de) 2001-04-11
AU5154999A (en) 1999-12-30
US20080124301A1 (en) 2008-05-29
DE69919869T2 (de) 2005-09-29
ES2226414T3 (es) 2005-03-16
EP1089764B1 (de) 2004-09-01
US8629117B2 (en) 2014-01-14
WO1999063975A3 (en) 2000-08-03

Similar Documents

Publication Publication Date Title
ATE274923T1 (de) Stimulierung des immunsystems
FR2679914B1 (fr) Composition de caoutchouc de la serie des dienes connjuguees.
MXPA02001911A (es) Anticuerpos ctla-4 humanos y sus usos.
DK0817847T4 (da) IL-17-receptor
WO2004017920A3 (en) Novel biphenyl and biphenyl-like cannabinoids
NL1003300A1 (nl) Implanteerbare therapeutische inrichting.
PT966447E (pt) Moleculas pequenas uteis no tratamento de doencas inflamatorias
CY1106234T1 (el) Συνθεσεις για τη θepαπεια μολυνσεων staphylococcus aureus
NZ312327A (en) Controlling hemipteran insect pests with bacillus thuringiensis
ATE253351T1 (de) Desodoriende zubereitungen enthaltend wasserlösliche -(1,3)-glucane
FR2805465B1 (fr) Nouvelles compositions pharmaceutique ou dietetiques a base de champignons
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
DE69102464T2 (de) Insektizide Zusammensetzung auf Basis von Bacillus Thuringiensis.
ITRM940149A0 (it) Dispositivo per volatilizzare nell'aria un ingrediente attivo, mediante combustione incompleta.
DE60225918D1 (de) Erförderers, bedienvorrichtung und auf diese weise gesteuertes fördersystem
DK0983361T3 (da) Bakterielle pheromoner og anvendelser deraf
IT9048066A0 (it) 2- amminotetraline-6, 7-sostituite attive come immunomodulanti e composizioni farmaceutiche che le contengono.
BR0009221A (pt) Vetores virais de inseto e usos dos mesmos
ATE255594T1 (de) Hepatitis b inhibitoren
IT8921412A0 (it) Bacillus thuringiensis var. donegani, preparato o tossina da esso ottenuta aventi attivita' insetticida contro i coleotteri.
FR2708855B1 (fr) Compositions pharmaceutiques immunoadjuvantes ou immunostimulantes.
IT239134Y1 (it) Dispositivo aspirante, particolarmente per w.c.
UA33424A (uk) Пристрій для профілактики та лікування постмастектомічного синдрому
IT1290938B1 (it) Complesso di sostanze naturali ad azione antiradicali liberi, sinergizzato da melatonina come antiossidante.
TH14994EX (th) สารเสริมฤทธิ์ทางอิมมูนและสารป้องกันการติดเชื้อ

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1089764

Country of ref document: EP